Update on Diffuse Large B-Cell Lymphoma for Newly Diagnosed Patients – November 14, 2024
Featuring: Dr. Matthew Lunning, University of Nebraska
Category Diffuse Large B-Cell Lymphoma
Haopeng Yang, PhD
Researcher Spotlight: Haopeng Yang, PhD UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER Super-enhancers are regions of the genome responsible for regulating expression of an unusually high number of genes. For his Lymphoma Research Foundation-funded project, Dr. Yang is characterizing the…
Min Xia, PhD
Researcher Spotlight: Min Xia, PhD WEILL CORNELL MEDICINE Among the different subtypes of diffuse large B-cell lymphoma (DLBCL), ABC-DLBCL represents one of the most aggressive forms with low response rates to standard chemotherapeutic approaches. Improved treatment approaches in this space…
Danielle Wallace, MD
Researcher Spotlight: Danielle Wallace, MD UNIVERSITY OF ROCHESTER Mindy Camp Fedida Memorial Scholar Older patients with diffuse large B-cell lymphoma (DLBCL) are often treated with lower doses of chemotherapy, which may contribute to an incomplete cure of the disease. Residual…
Jordan Goldstein, MD
Researcher Spotlight: Jordan Goldstein, MD STANFORD UNIVERSITY Errol M. Cook Memorial Scholar Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma, with many patients experiencing relapse after first-line therapy. Many patients now receive treatment with a chimeric…
Brian Sworder, MD, PhD
Researcher Spotlight: Brian Sworder, MD, PhD Stanford University School of Medicine Chimeric antigen receptor (CAR) T cells have shown to be incredibly beneficial for patients with lymphomawho have relapsed after chemotherapy. Unfortunately, however, several patients will still go on to relapse after…
Coraline Mlynarczyk, PhD
Researcher Spotlight: Coraline Mlynarczyk, PhD Joan & Sanford I. Weill Medical College of Cornell University Diffuse Large B Cell Lymphoma (DLBCL) is a heterogenous B-cell malignancy, with each patient presenting with a heavy and diverse burden of alterations in their DNA. Therefore,…
Rossella Marullo, MD, PhD
Researcher Spotlight: Rossella Marullo, MD, PhD Joan & Sanford I. Weill Medical College of Cornell University Two genomic studies revealed that 8 to 16 percent of diffuse large B-cell lymphoma (DLBCL) patients harborloss-of-function mutations in the gene TOX (TOXLOF). TOX is a…
Arushi Khurana, M.B.B.S
Researcher Spotlight: Arushi Khurana, M.B.B.S Mayo Clinic, Rochester, MN More than two-thirds of the newly diagnosed Diffuselarge B-cell lymphoma (DLBCL) patients are excluded from participating in clinical trials, without considering the structural and attitudinal barriers that preclude clinical trial participation. Over the…
David A. Bond, MD
Researcher Spotlight: David A. Bond, MD The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital Diffuse large B-cell lymphoma (DLBCL) is the mostcommon type of non-Hodgkin lymphoma (NHL). SinceDLBCL can advance quickly, it usually requires immediatetreatment, which…